<DOC>
	<DOCNO>NCT02268890</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic ( PK-the study way drug enters leave blood tissue time ) characteristic bortezomib administer intravenously Taiwanese participant multiple myeloma ( cancer type cell normally find bone marrow ) .</brief_summary>
	<brief_title>A Pharmacokinetic Study Bortezomib Taiwanese Participants With Multiple Myeloma</brief_title>
	<detailed_description>This Phase 4 , single-arm , open-label ( know intervention study ) , multicenter ( 1 hospital medical school team work medical research study ) study explore pharmacokinetics relapse ( return medical problem ) refractory ( respond treatment ) multiple myeloma . The study consist Screening phase bortezomib treatment phase define PK sample collection time point . Participants receive bortezomib intravenous injection two time week 2 week ( Days 1 , 4 , 8 , 11 ) follow 10-day resting phase ( Days 12 21 ) 1 treatment cycle . Pharmacokinetics primarily evaluate . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Diagnosis multiple myeloma base standard criterion Measurable , secretory multiple myeloma define serum monoclonal immunoglobulin ( Ig ) G &gt; = 10 gram per liter ( g/L ) , serum monoclonal IgA IgE great equal ( &gt; = ) 5 g/L , serum monoclonal IgD &gt; = 0.5 g/L , serum monoclonal IgM present ( regardless level ) , urine M protein &gt; = 200 mg/24 hour time point prior treatment Relapse progression myeloma follow prior systemic antineoplastic therapy meet indication approve drug leaflet . Relapse define : ) reappearance measurable disease ( define ) follow complete response ( CR ) ; b ) &gt; = 25 percent ( % ) increase serum urine Mprotein accord IMWG ( International Myeloma Working group ) criterion ; c ) development new worsen lytic bone disease ; ) new plasmacytoma &gt; =50 % increase long dimension exist plasmacytoma ; e ) worsen hypercalcemia ( correct serum calcium &gt; 11.5 milligram per deciliter [ mg/dL2.8 millimoles per liter [ mmol/L ] due multiple myeloma Karnofsky performance status &gt; =70 % Platelet count &gt; =50 Ã— 10^9 /L without transfusion support within 7 day laboratory test More 3 previous line therapy ( separate line therapy define single combination therapy either separated disease progression &gt; 6 month treatmentfree interval ) Peripheral neuropathy neuropathic pain National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCI CTCAE ) Version 4.03 Grade &gt; =2 Any follow within 3 week prior enrollment study : antineoplastic experimental therapy , corticosteroid use 10 mg/day ( prednisone equivalent ) , plasmapheresis Any follow within 2 week prior enrollment study : radiation therapy , major surgery ( kyphoplasty consider major surgery ) Prior malignancy multiple myeloma diagnose treat within last 2 year , exception completely resect carcinoma situ basal/squamous carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
</DOC>